177 related articles for article (PubMed ID: 8122371)
21. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
22. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction.
Huang X; Jin W; Hu K; Luo S; Du T; Griffin GE; Shattock RJ; Hu Q
Virology; 2012 Feb; 423(1):97-106. PubMed ID: 22192629
[TBL] [Abstract][Full Text] [Related]
23. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
McKeating JA; Cordell J; Dean CJ; Balfe P
Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
[TBL] [Abstract][Full Text] [Related]
24. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
[TBL] [Abstract][Full Text] [Related]
25. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes.
Botarelli P; Houlden BA; Haigwood NL; Servis C; Montagna D; Abrignani S
J Immunol; 1991 Nov; 147(9):3128-32. PubMed ID: 1717587
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop.
Hansen JE; Jansson B; Gram GJ; Clausen H; Nielsen JO; Olofsson S
Arch Virol; 1996; 141(2):291-300. PubMed ID: 8634021
[TBL] [Abstract][Full Text] [Related]
27. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
[TBL] [Abstract][Full Text] [Related]
28. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.
Tilley SA; Honnen WJ; Racho ME; Chou TC; Pinter A
AIDS Res Hum Retroviruses; 1992 Apr; 8(4):461-7. PubMed ID: 1376135
[TBL] [Abstract][Full Text] [Related]
29. The antigen/antibody specificity exchanger: a new peptide based tool for re-directing antibodies of other specificities to recognize the V3 domain of HIV-1 gp120.
Sällberg M; Sherefa K; Zhang ZX
Biochem Biophys Res Commun; 1994 Dec; 205(2):1386-90. PubMed ID: 7802674
[TBL] [Abstract][Full Text] [Related]
30. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES; Moore PL; Pantophlet RA; Morris L
J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
[TBL] [Abstract][Full Text] [Related]
31. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target.
Armstrong SJ; Dimmock NJ
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1397-402. PubMed ID: 8757979
[TBL] [Abstract][Full Text] [Related]
32. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.
Schønning K; Jansson B; Olofsson S; Nielsen JO; Hansen JS
Virology; 1996 Apr; 218(1):134-40. PubMed ID: 8615015
[TBL] [Abstract][Full Text] [Related]
33. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1.
Hioe CE; Hildreth JE; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):523-31. PubMed ID: 10221529
[TBL] [Abstract][Full Text] [Related]
34. Construction of reshaped human antibodies with HIV-neutralizing activity.
Maeda H; Matsushita S; Eda Y; Kimachi K; Tokiyoshi S; Bendig MM
Hum Antibodies Hybridomas; 1991 Jul; 2(3):124-34. PubMed ID: 1873503
[TBL] [Abstract][Full Text] [Related]
35. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.
Back NK; Smit L; Schutten M; Nara PL; Tersmette M; Goudsmit J
J Virol; 1993 Nov; 67(11):6897-902. PubMed ID: 8411395
[TBL] [Abstract][Full Text] [Related]
36. Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody.
Javaherian K; Zuchowski L; Clark FT
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1101-5. PubMed ID: 8554907
[TBL] [Abstract][Full Text] [Related]
37. Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 are chemically distinct.
Lederman S; Bergmann JE; Cleary AM; Yellin MJ; Fusco PJ; Chess L
AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1599-610. PubMed ID: 1457206
[TBL] [Abstract][Full Text] [Related]
38. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.
Poignard P; Fouts T; Naniche D; Moore JP; Sattentau QJ
J Exp Med; 1996 Feb; 183(2):473-84. PubMed ID: 8627160
[TBL] [Abstract][Full Text] [Related]
40. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.
Ringe R; Phogat S; Bhattacharya J
Virology; 2012 Apr; 426(1):34-41. PubMed ID: 22314018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
